Williams Cancer Institute

Menu
Menu
Colon cancer (colorectal) · Interventional immuno-oncology

Built for the 95% of colorectal cancers standard immunotherapy can’t see.

Most colorectal cancers are invisible to standard immunotherapy. Our needle-based approach is built to change that — especially when treatment has stopped working.

Personalized

Minimally invasive

Immune-activating

Outpatient

In plain terms

What we do, in three paragraphs.

Most metastatic colorectal cancer faces an immune-treatment gap. About 1 in 20 cases are MSI-high and respond well to standard immunotherapy — but the other ~95% are MSS (microsatellite-stable: “cold”, nearly invisible to the immune system), and standard checkpoint drugs don’t work for them. Our approach is built for that gap: ablation plus intratumoral immunotherapy through a single needle, in one outpatient session.
For MSS tumors the problem isn’t the drug — it’s that the immune system was never “invited” to the tumor. Breaking it open with PEF or cryoablation releases its hidden “fingerprints” and turns it “hot” — AblationVax, aiming for the abscopal effect plus lasting immune memory.
Because colorectal cancer so often spreads to the liver, we also offer an intra-arterial option — delivering immunotherapy through the artery that feeds the liver, concentrating it there while sparing the rest of the body. We coordinate with your oncology team, support the whole patient (including microbiome care), and most patients finish in about a week. Results vary.

One needle, one session: ablation plus immunotherapy delivered where the cancer lives.

AblationVax: the treated tumor teaches your immune system to attack cancer body-wide.

Real outcomes

MSS disease that has stopped responding.

After progression on FOLFOX / FOLFIRI + biologics and mutation-targeted therapy, options narrow. Our approach is designed for that MSS gap: re-engage immunity at the tumor site.

Individual results vary. These outcomes represent specific patient cases and are not guaranteed for all patients.

Where our approach fits

Treatment options by stage.

Find your diagnosis below to see what standard care offers, where we add to it, and what role our approach plays.

Early (stage I–III)

Standard care
Surgery + adjuvant chemo.
What we add
Our approach is rarely first-line at this stage.
Standard care first

Oligometastatic (liver / lung-limited)

Standard care
Ablation is established for liver-only or lung-only disease.
What we add
We add intratumoral immune priming to drive systemic memory beyond the treated sites.
Local + systemic strategy

Our primary focus

Metastatic MSS

Standard care
Chemo + biologic backbone; checkpoint monotherapy historically fails.
What we add
Ablation + intratumoral immune stimulation to convert cold to hot.

MSS tumors block T-cell infiltration — without T-cells already inside, IV checkpoint drugs have nothing to activate. Ablation reseeds the response.

Systemic immune activation

Metastatic MSI-H

Standard care
Pembrolizumab or nivolumab + ipilimumab.
What we add
Considered for selected cases progressing on standard checkpoint blockade.
Re-engagement after IV failure

Beyond ablation alone

Destroy the tumor, then teach your immune system to finish the job.

Standard approaches
Our approach — AblationVax
MSI-H: checkpoint blockade. MSS: chemo + biologics, limited immune options.
Ablation + intratumoral immunotherapy to drive immune engagement in MSS disease.

Liver-only oligomet: ablation alone.
Ablation + immune amplification + intra-arterial hepatic infusion in selected cases.

IV checkpoint blockade: standard systemic exposure.
Delivered directly into the tumor rather than through the bloodstream. The aim is to concentrate treatment at the tumor site and limit whole-body exposure.

Why this approach for colorectal cancer?

Treats tumors near critical structures

Liver, pelvis, peritoneum, vasculature — PEF’s non-thermal mechanism allows treatment near the portal vein, IVC, and hepatic artery.

Converts “cold” MSS tumors into “hot” targets

Ablation releases tumor antigens and danger signals; intratumoral immunotherapy amplifies the response — addressing the MSS gap directly.

Aims for systemic response

The investigational goal is to determine whether treating one tumor can build lasting immune memory against untreated metastatic sites.

Colorectal-specific breakthrough

Converting MSS cold tumors and targeting liver-dominant disease.

“Microsatellite-stable colorectal cancer is the textbook immune-cold tumor. Standard checkpoint blockade doesn’t work — not because the drug is wrong, but because the immune system was never invited into the site. Our approach changes that.”

— Dr. Jason R. Williams

Ablation as immune trigger

PEF or cryoablation releases broad antigen pools and danger signals — the trigger that conventional immunotherapy lacks in MSS disease.

Intra-arterial delivery for liver disease

For liver-dominant disease, hepatic-artery infusion delivers high local concentrations while sparing systemic toxicity — supported by growing intra-arterial evidence.

Multi-agent cocktails

CpG, OX40 / CD40 agonists, and checkpoint inhibitors delivered intratumorally to re-engage MSS patients who have exhausted every standard line.

“Liver-dominant metastatic colorectal cancer is one of the most actionable contexts for intratumoral immune approaches. The immune system needs to be invited back.” — Dr. Williams

Beyond the procedure: whole-patient support.

We optimize your entire system for the best possible response — and coordinate with the team you already have.

Gut microbiome optimization

Diet, probiotics, and related therapies to support a stronger immunotherapy response.

Off-label protocols

Strategic use of repurposed medications to enhance immune response.

Personalized cocktails

Multi-agent immunotherapy tailored to your specific cancer.

Oncologist coordination

We work alongside your current chemo and radiation team.

What to expect

Your path to treatment.

1

Case review

We review your CT abdomen / pelvis / chest, PET, and biomarker reports (MSI/dMMR, KRAS, NRAS, BRAF, HER2).

2

Protocol design

A personalized cocktail tuned to MSI status, mutation profile, and prior therapy.

3

Procedure week

Image-guided PEF or cryoablation + intratumoral immunotherapy. Outpatient.

4

Follow-up

Imaging at 6–8 weeks, coordination with your home oncology team.

Procedure ~1 hour

Recovery ~2 hours

All outpatient

Is this right for you?

You may be a candidate if:

✓Metastatic MSS disease progressing on chemo + biologics
✓Liver-dominant oligometastatic disease
✓Progression on BRAF, HER2, or KRAS G12C targeted therapy
✓MSI-H disease progressing on IV checkpoint blockade
✓Seeking immune options after MSS standard sequences are exhausted

It may not be suitable if:

—Diffuse peritoneal carcinomatosis without a focal target
—Severe hepatic insufficiency
—Active severe infection
—Uncorrectable bleeding disorders
—Very poor performance status (ECOG ≥ 3)

Each case is individually evaluated by Dr. Williams’ team.

Track record

Innovation for colorectal cancer.

2008

Cryoablation for liver and abdominal tumors

Image-guided ablation across abdominal disease.

2014

Multi-agent intratumoral protocols

The AblationVax concept.

Now

PEF + intratumoral combinations for MSS disease

OX40 / CD40 / CpG / checkpoint combinations plus intra-arterial options for liver-dominant disease.

Ready to move forward?

There is more ahead. Take the next step with confidence.

Complimentary evaluation.

Dr. Williams’ team will personally review your case and imaging — no cost, no obligation.

Or email info@williamscancerinstitute.com

Beverly Hills · San Jose del Cabo · Mexico City — most patients complete treatment in one week

(theme footer continues — owned by Astra)

Menu

Email Signup